Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06357806
NA

The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients

Sponsor: Beijing 302 Hospital

View on ClinicalTrials.gov

Summary

This is a prospective, open-labled, randomized controlled study to assess efficacy and safety of treatment with Sintilimab (PD-1 antibody) combined Peg-IFNα-2b in CHB patients on stable NAs treatment.

Official title: The Safety and Efficacy of PD-1 Antibody Combined With Pegylated Interferon-α Therapy to Promote the Clinical Cure in Nucleoside (Acid) Analogues-suppressed Chronic Hepatitis B Patients: A Protocol for the Prospective Pilot Study

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

45

Start Date

2024-05-17

Completion Date

2026-10-08

Last Updated

2026-03-18

Healthy Volunteers

No

Interventions

DRUG

Sintilimab

100mg/10ml/1bottle

DRUG

Peg-IFNα-2b

180ug/0.5ml/1bottle

DRUG

NAs

tablets

Locations (1)

the Fifth Medical Center, Chinese PLA General Hospital

Beijing, Beijing Municipality, China